Literature DB >> 11829204

Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. A general practitioner-based survey in France.

F Clinard1, M Bardou, C Sgro, N Lefevre, F Raphael, F Paille, M Dumas, P Hillon, C Bonithon-Kopp.   

Abstract

BACKGROUND AND AIM: Non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the most frequently prescribed drugs. Gastrointestinal damage, the most common side effect of NSAIDs. can be limited by the prescription of cytoprotective agents. In order to assess determinants of NSAID-associated cytoprotective agent prescriptions in primary care practice, we performed a general practitioner (GP)-based study.
METHODS: After a 2-month intensive information campaign, the participation of all GPs of the Côte d'Or (France) administrative area was requested. During a 2-month period, GPs had to return a mailed questionnaire on NSAID prescription for up to ten consecutive patients aged over 18 years who required NSAIDs. This 30-item questionnaire included questions about the patient, the type of NSAID and the GP.
RESULTS: GP participation rate was 24%, and 791 prescriptions were provided. GPs who participated in the study were representative of GPs of the area in terms of sex, time elapsed since graduation and GP practice area. Around 80% of the patients included in the study were under the age of 65 years. The proportion of prescriptions combining NSAIDs and gastroprotective agents was 29.5%. Omeprazole accounted for 58% of the coprescriptions and misoprostol for 29%. Independent determinants associated with the co-prescription of a cytoprotective agent were age [odds ratio (OR) 4.1; confidence interval (CI) 95% 2.3 7.4], previous history of poor NSAID tolerance (OR 10.4; CI 95% 5.8-18.6), previous history of moderate to severe digestive disorders (OR 13.4; CI 95% 5.1 35.4) and indication for chronic illness (OR 1.8, CI 95% 1.1-3.1). Prescriptions of cytoprotective drugs were in conformity with official guidelines for 78.3% of the patients. Although around 60% of the patients with risk factors for poor tolerance received a gastroprotective drug, 50% of the patients over 65 years did not receive it. Conversely, nearly 12% of the patients with no risk factors were prescribed cytoprotective agents. Patient history was the main reason put forward by GPs for prescribing cytoprotective drugs.
CONCLUSION: Although a large majority of GP prescriptions were in accordance with official recommendations, inadequate NSAID prescription practices remain relatively frequent especially with regard to the elderly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11829204     DOI: 10.1007/s00228-001-0378-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Gastroprotection during the administration of non-steroidal anti-inflammatory drugs. A drug-utilization study.

Authors:  Alfonso Carvajal; Luis H Martín Arias; Eva Vega; José Antonio García Sánchez; Igor Martín Rodríguez; Pilar García Ortega; Javier García del Pozo
Journal:  Eur J Clin Pharmacol       Date:  2004-06-23       Impact factor: 2.953

2.  Association between adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs and the incidence of gastric mucosal lesions in Japanese patients.

Authors:  Hidetaka Tsumura; Tsuyoshi Fujita; Isamu Tamura; Yoshinori Morita; Masaru Yoshida; Takashi Toyonaga; Hidekazu Mukai; Hideto Inokuchi; Hiromu Kutsumi; Takeshi Azuma
Journal:  J Gastroenterol       Date:  2010-05-25       Impact factor: 7.527

3.  Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study.

Authors:  Viktorija Erdeljic; Igor Francetic; Viola Macolic Sarinic; Marinko Bilusic; Ksenija Makar Ausperger; Mirjana Huic; Iveta Mercep
Journal:  Pharm World Sci       Date:  2006-11-17

4.  The use of drugs is not as rational as we believe… but it can't be! The emotional roots of prescribing.

Authors:  Albert Figueras
Journal:  Eur J Clin Pharmacol       Date:  2011-03-23       Impact factor: 2.953

5.  Use of gastrointestinal prophylaxis in NSAID patients: a cross sectional study in community pharmacies.

Authors:  Elsa López-Pintor; Blanca Lumbreras
Journal:  Int J Clin Pharm       Date:  2011-03-12

Review 6.  Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole.

Authors:  Antonio Gigante; Ignacio Tagarro
Journal:  Clin Drug Investig       Date:  2012-04-01       Impact factor: 2.859

7.  Inadequate use of preventive strategies in patients receiving NSAIDs.

Authors:  I Francetic; M Bilusic; V Macolic-Sarinic; M Huic; I Mercep; K Makar-Ausperger; V Erdeljic; S Mimica; I Baotic; P Simic
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

8.  Interobserver variation in the endoscopic diagnosis of gastroduodenal ulcer scars: implications for clinical management of NSAIDs users.

Authors:  Yuji Amano; Goichi Uno; Takafumi Yuki; Mayumi Okada; Yasumasa Tada; Nobuhiko Fukuba; Norihisa Ishimura; Shunji Ishihara; Yoshikazu Kinoshita
Journal:  BMC Res Notes       Date:  2011-10-13

Review 9.  Treatment costs to prevent or treat upper gastrointestinal adverse events associated with NSAIDs.

Authors:  Elham Rahme; Alan N Barkun; Viviane Adam; Marc Bardou
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.